Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, August 18, 2017 9:22:22 AM
August 17, 2017 - By Linda Rogers
https://kgazette.com/triple-frond-partners-lowered-visa-v-holding-6-analysts-bullish-bioline-rx-ltd-blrx/
Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 13 analyst reports since July 27, 2015 according to SRatingsIntel.
Maxim Group maintained the shares of BLRX in report on Monday, July 10 with “Buy” rating.
On Thursday, May 18 the stock rating was upgraded by Maxim Group to “Buy”. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright.
The rating was maintained by Oppenheimer on Tuesday, August 8 with “Buy”. H.C. Wainwright maintained Bioline RX Ltd (NASDAQ:BLRX) rating on Friday, June 2. H.C. Wainwright has “Buy” rating and $4.00 target. The firm earned “Buy” rating on Friday, May 26 by H.C. Wainwright. The firm has “Buy” rating given on Thursday, June 1 by Maxim Group. The company was maintained on Tuesday, August 8 by Maxim Group. The rating was initiated by Roth Capital with “Buy” on Thursday, August 3. The firm earned “Hold” rating on Friday, August 12 by Maxim Group. See Bioline RX Ltd (NASDAQ:BLRX) latest ratings:
08/08/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0000 Maintain
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
08/08/2017 Broker: Maxim Group Rating: Buy New Target: $3.0000 Maintain
04/08/2017 Broker: Oppenheimer Rating: Outperform New Target: $3 Initiates Coverage On
03/08/2017 Broker: Roth Capital Rating: Buy New Target: $3.0000 Initiate
10/07/2017 Broker: Maxim Group Rating: Buy New Target: $3.0000 Maintain
02/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
01/06/2017 Broker: Maxim Group Rating: Buy New Target: $3.0000 Maintain
26/05/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
18/05/2017 Broker: Maxim Group Old Rating: Hold New Rating: Buy Upgrade
Recent BLRX News
- BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection • PR Newswire (US) • 09/17/2024 05:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 08:30:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 11:06:39 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/18/2024 08:05:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 11:16:29 AM
- U.S. Futures Present Mixed Pre-Market Performance, Oil Prices Surge • IH Market News • 05/28/2024 11:31:04 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 11:11:36 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 11:05:21 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 09:07:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 11:14:18 AM
- BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting • PR Newswire (US) • 04/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 12:47:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 12:08:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 12:07:06 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/08/2024 05:15:22 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/29/2023 09:20:42 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/29/2023 09:15:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 12:05:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/12/2023 12:07:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 12:03:18 PM
- Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more • IH Market News • 11/20/2023 11:25:08 AM
- BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ Ventures • PR Newswire (Canada) • 11/01/2023 11:43:00 AM
- BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • PR Newswire (Canada) • 10/31/2023 01:00:00 PM
- BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/26/2023 06:18:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM